Research Analysts Set Expectations for HURA Q3 Earnings

Key Points

• Brookline Capital Markets lowered its Q3 2026 EPS estimate for TuHURA Biosciences to a loss of $0.15 per share from $0.13 previously. The firm projects full-year 2026 EPS of negative $0.58, compared with the current consensus estimate of negative $0.55.
• Analyst sentiment remains broadly positive, with five Buy ratings and one Sell rating, resulting in a Moderate Buy consensus and a $9.00 average price target. Recent targets include $9.00 from Citizens JMP and $10.00 from HC Wainwright.
• HURA shares opened at $1.99 and have traded between $0.41 and $3.43 over the past year. The company reported a Q2 loss of $0.14 per share, slightly better than analysts’ expected $0.15 loss.

TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Research analysts at Brookline Capital Markets lowered their Q3 2026 earnings per share (EPS) estimates for TuHURA Biosciences in a note issued to investors on Monday, October 26th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings of ($0.15) per share for the quarter, down from their previous forecast of ($0.13). The consensus estimate for TuHURA Biosciences' current full-year earnings is ($0.55) per share. Brookline Capital Markets also issued estimates for TuHURA Biosciences' Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at ($0.07) EPS.

Several other research analysts have also recently weighed in on HURA. Citizens Jmp reissued a "market outperform" rating and set a $9.00 price objective on shares of TuHURA Biosciences in a report on Tuesday, August 18th. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of TuHURA Biosciences in a report on Tuesday. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

TuHURA Biosciences Price Performance

HURA opened at $1.99 on Thursday. The company's 50-day simple moving average is $2.03 and its two-hundred day simple moving average is $1.94. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.18 and a current ratio of 0.18. The stock has a market capitalization of $126.82 million, a P/E ratio of -3.69 and a beta of -0.21. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $3.43.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HURA. Two Sigma Securities LLC bought a new position in shares of TuHURA Biosciences in the 2nd quarter worth approximately $33,000. Merck & Co. Inc. grew its position in TuHURA Biosciences by 39.4% during the first quarter. Merck & Co. Inc. now owns 19,445 shares of the company's stock valued at $35,000 after buying an additional 5,495 shares during the period. Sanctuary Advisors LLC purchased a new stake in TuHURA Biosciences during the second quarter valued at approximately $49,000. Deutsche Bank AG bought a new position in TuHURA Biosciences in the 2nd quarter worth $52,000. Finally, PFG Investments LLC lifted its position in shares of TuHURA Biosciences by 39.4% during the 1st quarter. PFG Investments LLC now owns 32,630 shares of the company's stock valued at $58,000 after buying an additional 9,219 shares in the last quarter. Institutional investors own 0.62% of the company's stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company's research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA's lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.